There are 2789 resources available
611P - Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
Presenter: Emmanuel Antonarakis
Session: ePoster Display
691P - Effect of NANOGNB mutations on DNA damage response and efficacy of immune checkpoint inhibitors in advanced renal clear cell carcinoma
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract
692P - Characterization of the tumor immune microenvironment in early-stage clear cell renal cell carcinoma (ccRCC): Prognostic value of an M0-macrophage enriched subtype
Presenter: Mark Farha
Session: ePoster Display
693P - Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy
Presenter: Maryam Soleimani
Session: ePoster Display
694P - Methylthioadenosine phosphorylase (MTAP) deletion is more common in sarcomatoid (srcRCC) than in clear cell renal cell carcinoma (ccRCC)
Presenter: Andrea Necchi
Session: ePoster Display
695P - Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
Presenter: Marzia Del Re
Session: ePoster Display
617P - Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project
Presenter: Taigo Kato
Session: ePoster Display
618P - Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
Presenter: John Shen
Session: ePoster Display